Shots:

• The US FDA has cleared an IND application to initiate a P-II trial evaluating tovinontrine in 170 patients aged ≥45yrs. with persistent HFpEF symptoms with enriched PDE9 expression for 16wks. The trial is expected to initiate in Q2’22
• The 1EPs will be changed in NT-proBNP & 2EPs includes safety, tolerability along with QoL measures such as KCCQ and NYHA classification while exploratory measures include a clinical composite score, 6MWT & evaluation of cardiac structure and function
• Tovinontrine is a highly selective and potent small-molecule PDE9 inhibitor. Additionally, in vitro data showed superior potency & selectivity along with minimal brain penetration compared to other PDE9 inhibitors

Ref: Globe Newswire | Image: Globe Newswire